復宏漢霖(02696.HK)兩個產品獲歐盟委員會批准用於特定人群骨質疏鬆症治療等適應症
復宏漢霖(02696.HK)公布,近日BILDYOS以及BILPREVDA兩個產品的上市許可申請(MAAs),已獲歐盟委員會批准,該等商品名由N.V. Organon於歐盟註冊商標。此次獲批意味著兩個產品在所有歐盟成員國及冰島、列支敦士登和挪威獲得集中上市許可。
獲批適應症為Prolia與XGEVA於歐盟上市的所有適應症,具體而言:
BILDYOS適應症為骨折高風險的絕經後婦女及男性的骨質疏鬆症治療;骨折高風險的前列腺癌男性與激素消融相關的骨質流失治療;及骨折高風險的成年患者中與長期全身糖皮質激素治療相關骨質流失的治療。
BILPREVDA適應症包括預防成人晚期骨惡性腫瘤的骨相關事件;及不可手術切除或手術切除後可能導致嚴重功能障礙的骨巨細胞瘤患者的治療,包括成人和骨骼發育成熟的青少年患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.